A Phase 2a, Randomized, Placebo-Controlled Human Challenge Trial to Evaluate the Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated with Respiratory Syncytial Virus

A Phase 2a, Randomized, Placebo-Controlled Human Challenge Trial to Evaluate the Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated with Respiratory Syncytial Virus

Abstract Introduction Human respiratory syncytial virus (RSV) infections can result in hospitalization and/or death among vulnerable populations. Molnupiravir is a prodrug of ß-D-N4-hydroxycytidine, which has broad-spectrum preclinical activity against RNA viruses. We conducted a pilot trial evaluat...

Full description

Saved in:
Bibliographic Details
Main Authors: Mickie H. Cheng, Alex J. Mann, Brian M. Maas, Tian Zhao, Melissa Bevan, Andrea K. Schaeffer, Laura E. Liao, Andrew P. Catchpole, David W. Hilbert, S. Aubrey Stoch, Carisa S. De Anda
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-04-01
Series:Pulmonary Therapy
Subjects:
RSV
Antiviral
Clinical trial
hVCM
Human challenge
Molnupiravir
Online Access:https://doi.org/10.1007/s41030-025-00289-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s41030-025-00289-z

Similar Items